Photo from wikipedia
To report the results of a 104‐week extension to a 52‐week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM)… Click to show full abstract
To report the results of a 104‐week extension to a 52‐week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM) in participants with type 2 diabetes (T2D) receiving background metformin.
Keywords:
week extension;
dapagliflozin plus;
results 104;
extension week;
104 week;
week
Journal Title: Diabetes
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!